Frequent
Cough

Respiratory
Infections

Shortness of
Breath

General
Fatigue

02

Live Biotherapeutic Product (LBP)

• Defined consortium of "natural" live bacteria

03

• Synergism compared to individual species

• Prevent or treat pathological inflammation

Ghent University
BactoRelief

04

Formulation containing LBP

Freeze-drying

Product

Chronic lung
inflammation ↓

Nebulization

Saline

The Solution

Ghent University
BactoRelief

05

High unmet clinical need

1,163,411 patients in US, UK, Germany

Projected market growth

(965,8 million USD by 2031)

Market opportunity of BactoRelief

Ghent University
BactoRelief

Competitive landscape and USP

Other LBPs
for lung diseases

4 Pipeline LBPs (preclinical)
Disease: Asthma, COPD, IPF, ARDS, bronchiectasis
Product: Lactobacillus-based
Delivery: Inhalation

1 Pipeline LBPs (preclinical)
Disease: Pneumonia
Product: Lactobacillus/Mycobacterium-based
Delivery: Inhalation

06

Differentiator

Reclaiming health with natural bacteria

Ghent University
BactoRelief

Competitive landscape and USP

Other LBPs
for lung diseases

4 Pipeline LBPs (preclinical)
Disease: Asthma, COPD, IPF, ARDS, bronchiectasis
Product: Lactobacillus-based
Delivery: Inhalation

1 Pipeline LBPs (preclinical)
Disease: Pneumonia
Product: Lactobacillus/Mycobacterium-based
Delivery: Inhalation

07

Approved LBPs

Treatment recurrent C. difficile infections (gut)

Other anti-inflammatory drugs

Phase 3 trial successful (28/5/24)
Disease: Bronchiectasis
Product: DPP1 inhibitor
Delivery: oral

Brensocatib

Ghent University
BactoRelief

Status of technology

08

Ghent University
BactoRelief

Status of technology

09

Ghent University
BactoRelief

Status of technology

10

Ghent University
BactoRelief

Status of technology

11

Freeze-dried formulation
with cryoprotectans

Long-term storage
(up to 1 year) 

Nebulization

Ghent University
BactoRelief

IP

12

• “Bacterial compositions with anti-inflammatory activity”
• LBP based on combinations of at least two species of anti-inflammatory genus
• Applications for diverse inflammatory diseases
• National phase EPO and USPTO

Ghent University
BactoRelief

Roadmap

13

IOF  Stepstone

Seed Funding (6-7M)

Series a Funding

Lead LBP to candidate LBP

Candidate LBP to first-in-human

Investment
ready

IND
ready

Start
first-in-human trials

BactoRelief

Launch of

Jan
2025

Jan
2027

Jan
2029

1) Dose response studies in rodents

2) Comparison (future) standard-of-care + combination SoC with BactoRelief in vivo

3) Regulatory gap analysis

4) Business planning

5) Team creation

1) Safety in large animal model

2) Upscaling

3) CMC

4) Assembling IMDP

Ghent University
BactoRelief

Team

14

Principal investigators

Lead scientist

Entrepreneur in residence

Scientist

Technician

Prof. Aurélie Crabbé

Prof. Tom Coenye

Apr. Axelle Van Daele
(PhD student)

UGent

valorisation officer

Dr. Eline Soetens

Advisory board

Marie-Laure Vervynck

(BSc)

To be recruited 2025

To be recruited 2026

UGent business

developer

RPh. Sarah Braet

(EMBA)

• What data (or other aspects of the spin-off project) do you consider critical to be "investor-ready" to enable launch of BactoRelief?

  • Our current 2-year plan to further de-risk BactoRelief (with UGent IOF funding):

    • ​Dose-response studies in small animal model (safety and efficacy)

    • Formulation and delivery

    • Regulation and business development

• What are your thoughts about the spin-off team, and would you have suggestions for key expertise in the advisory board?

Questions

Ghent University
BactoRelief

15